• 54737 Citations
1976 …2023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

I have been an active clinical investigator vested in the immune-based therapy of melanoma. This has led to my role in the clinical development of initially Interleukin-2 and more recently anti-CTLA-4 and anti-PD1/PDL-1. While checkpoint therapy has been a great breakthrough in cancer treatment, additional immune-based strategies are still critically needed. Efforts to identify mechanisms of resistance to checkpoint inhibitors and approaches to overcome de novo and acquired resistance are one of my major interest. In addition I have ongoing efforts in the personalized therapy of melanoma with well-defined targets (BRAF v600, NRAS mutations, CKIT mutations). I co-lead the Northwestern Cancer Center Translational Research in Solid Tumors (TRIST) program which is critical to the success of the Cancer Center. In this role, I am working to bring translational studies including immunotherapy based trials to all solid tumors. The development of translational studies that will provide a better understanding to sensitivity and resistance to both immune checkpoint therapy and targeted therapy is my highest priority. As Co-Leader of TRIST program, I am determined to bring creative immune based trials to cancers .

Training Experience

1982Internship, University of Chicago Hospitals
1985Residency, University of Chicago Hospitals
1986Residency, University of Wisconsin Hospital & Clinics
1989Fellowship, University of Wisconsin Hospital & Clinics

Education/Academic qualification

MD, Albert Einstein College

… → 1981


  • Genomic Medicine/Personalized Medicine
  • Immunology
  • Kidney Cancer / Urinary Tract Cancer
  • Skin Cancer

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

Melanoma Medicine & Life Sciences
Interleukin-2 Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2011 2023

Regulatory T-Lymphocytes
Immunosuppressive Agents
Tumor Microenvironment

Research Output 1976 2019

Clinical characterization of colitis arising from anti-PD-1 based therapy

Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A. W., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 othersGibney, G. T., Rapisuwon, S., Eroglu, Z., Sullivan, R. & Johnson, D. B., Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.

Research output: Contribution to journalArticle


A critical need for better cancer immunotherapy models: Are organotypic tumor spheroid cultures the answer?

Balko, J. M. & Sosman, J. A., Feb 1 2018, In : Cancer Discovery. 8, 2, p. 143-145 3 p.

Research output: Contribution to journalArticle

7 Citations

Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations

Kugel, C. H., Douglass, S. M., Webster, M. R., Kaur, A., Liu, Q., Yin, X., Weiss, S. A., Darvishian, F., Al-Rohil, R. N., Ndoye, A., Behera, R., Alicea, G. M., Ecker, B. L., Fane, M., Allegrezza, M. J., Svoronos, N., Kumar, V., Wang, D. Y., Somasundaram, R., Hu-Lieskovan, S. & 23 othersOzgun, A., Herlyn, M., Conejo-Garcia, J. R., Gabrilovich, D., Stone, E. L., Nowicki, T. S., Sosman, J. A., Rai, R., Carlino, M. S., Long, G. V., Marais, R., Ribas, A., Eroglu, Z., Davies, M. A., Schilling, B., Schadendorf, D., Xu, W., Amaravadi, R. K., Menzies, A. M., McQuade, J. L., Johnson, D. B., Osman, I. & Weeraratna, A. T., Nov 1 2018, In : Clinical Cancer Research. 24, 21, p. 5347-5356 10 p.

Research output: Contribution to journalArticle

Regulatory T-Lymphocytes
1 Citations

A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600-mutant solid tumors

Yam, C., Xu, X., Davies, M. A., Gimotty, P. A., Morrissette, J. J. D., Tetzlaff, M. T., Wani, K. M., Liu, S., Deng, W., Buckley, M., Zhao, J., Amaravadi, R. K., Haas, N. B., Kudchadkar, R. R., Pavlick, A. C., Sosman, J. A., Tawbi, H., Walker, L., Schuchter, L. M., Karakousis, G. C. & 1 othersGangadhar, T. C., Jan 1 2018, In : Clinical Cancer Research. 24, 1, p. 22-32 11 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinases
26 Citations

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., Lane, S., Lee, D. Y., Kaper, M., McKean, M., Beckermann, K. E., Rubinstein, S. M., Rooney, I., Musib, L., Budha, N., Hsu, J. & 26 othersNowicki, T. S., Avila, A., Haas, T., Puligandla, M., Lee, S., Fang, S., Wargo, J. A., Gershenwald, J. E., Lee, J. E., Hwu, P., Chapman, P. B., Sosman, J. A., Schadendorf, D., Grob, J. J., Flaherty, K. T., Walker, D., Yan, Y., McKenna, E., Legos, J. J., Carlino, M. S., Ribas, A., Kirkwood, J. M., Long, G. V., Johnson, D. B., Menzies, A. M. & Davies, M. A., Mar 1 2018, In : The Lancet Oncology. 19, 3, p. 310-322 13 p.

Research output: Contribution to journalArticle

Body Mass Index
Drug Therapy